Structure Therapeutics, Inc. Sponsored ADR (GPCR) Price & Analysis

Compare

1,157 Followers

GPCR Stock Chart & Stats

$71.29

-$0.32(-1.18%)

At close: Jan 08 4:00 PM EST

$71.29

-$0.32(-1.18%)

Day’s Range― - ―

52-Week Range$13.22 - $94.90

Previous CloseN/A

Volume219.80K

Average Volume (3M)2.13M

Market Cap

$4.33B

Enterprise Value$845.76M

Total Cash (Recent Filing)$799.04M

Total Debt (Recent Filing)$7.09M

Price to Earnings (P/E)―

Beta1.15

Next Earnings

Mar 26, 2026

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding70,639,190

10 Day Avg. Volume2,034,111

30 Day Avg. Volume2,125,308

Financial Highlights & Ratios

PEG Ratio3.15

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-12.11

Enterprise Value/Market Cap0.20

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.23K

Enterprise Value/Ebitda-3.55

Forecast

1Y Price Target

$101.55

Price Target Upside42.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-1.33

Revenue Forecast (FY)$1.06M

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyAleniglipron demonstrated potential best-in-class weight loss, a competitive tolerability profile with room for further optimization in Ph3, and a clean safety profile with no hepatic signal.

Investment OutlookAnalyst recommends a Buy/High Risk rating for the stock, indicating a positive outlook.

Market PotentialOral GLP-1s are set to become Tier 1 therapies driven by payer economics, and the current valuation is viewed as a massive arbitrage opportunity with strong M&A potential.

Bears Say

Adverse EffectsThere appears to be a higher frequency of vomiting in the Phase IIb aleniglipron program versus the ACHIEVE-1 trial of orforglipron.

Market PerceptionRecent data with Lilly's orfoglipron showed mixed reviews, with obesity results underperforming expectations, impacting market perception.

Market SentimentShort interest in the company's stock is 13.3% of the float, indicating some bearish sentiment in the market.

Structure Therapeutics, Inc. Sponsored ADR News

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $60...

6d ago

GPCR

Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671

Structure Therapeutics (GPCR) announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s...

8d ago

GPCR

Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Structure Therapeutics (GPCR) to $125 from $120...

13d ago

GPCR

Structure Therapeutics price target raised to $120 from $87 at Citizens

Citizens raised the firm’s price target on Structure Therapeutics (GPCR) to $120 from $87 and keeps an Outperform...

14d ago

GPCR

Structure Therapeutics price target raised to $125 from $79 at Jefferies

Jefferies raised the firm’s price target on Structure Therapeutics (GPCR) to $125 from $79 and keeps a Buy...

14d ago

GPCR

Structure Therapeutics 8.5M share Spot Secondary priced at $65.00

Jefferies, Leerink, Goldman Sachs, Morgan Stanley, Guggenheim and BMO Capital acted as joint book running managers for the...

16d ago

GPCR

Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk

Biotech Structure Therapeutics’ ($GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped competing...

16d ago

LLY

NVO

Why is Biotech Stock iBio Up over 50%?

Shares of Texas-based biotech firm iBio ($IBIO) have climbed as high as 50% over the past 24 hours....

16d ago

EVR

LLY

Structure Therapeutics price target raised to $100 from $60 at Citi

Citi analyst Samantha Semenkow raised the firm’s price target on Structure Therapeutics (GPCR) to $100 from $60 and...

16d ago

GPCR

Structure Therapeutics price target raised to $99 from $61 at Clear Street

Clear Street raised the firm’s price target on Structure Therapeutics (GPCR) to $99 from $61 and keeps a...

17d ago

LLY

GPCR

Structure Therapeutics announces proposed offering of $500M in ADS

Structure Therapeutics (GPCR) “announced the commencement of a proposed underwritten public offering, subject to market and other conditions,...

17d ago

GPCR

Structure Therapeutics price target raised to $90 from $50 at Stifel

Stifel raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $50 and keeps a Buy...

17d ago

GPCR

These 3 Stocks Could Explode Higher, Say Five-Star Analysts – 11/28/2025

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe...

27d ago

GPCR

TBPH

Structure Therapeutics Announces $650 Million Public Offering

An update from Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) is now available. On December 9, 2025,...

15d ago

GPCR

GPCR FAQ

What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?

Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $94.90 in the past 12 months.

What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?

Structure Therapeutics, Inc. Sponsored ADR’s market cap is $4.33B.

When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?

Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 26, 2026 which is in 91 days.

How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?

Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$0.005.

Is Structure Therapeutics, Inc. Sponsored ADR overvalued?

According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?

Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.

What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?

Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.38.

How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?

Structure Therapeutics, Inc. Sponsored ADR has 70,639,190 shares outstanding.

What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?

Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -1.882%.

Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?

Currently, no hedge funds are holding shares in GPCR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-25.31%

Trailing 12-Months

Asset Growth

-10.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Earnings & Revenues

Historic Earnings Reports

GPCR Stock 12 Month Forecast

Average Price Target

$101.55

▲(42.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","42":"$42","70":"$70","98":"$98","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,42,70,98,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,41.526153846153846,48.48230769230769,55.43846153846154,62.39461538461539,69.35076923076923,76.30692307692308,83.26307692307694,90.21923076923078,97.17538461538462,104.13153846153847,111.08769230769232,118.04384615384618,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,39.722307692307695,44.87461538461538,50.026923076923076,55.17923076923077,60.33153846153846,65.48384615384614,70.63615384615383,75.78846153846153,80.94076923076923,86.09307692307692,91.24538461538461,96.3976923076923,{"y":101.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,36.91076923076923,39.25153846153846,41.59230769230769,43.933076923076925,46.27384615384615,48.614615384615384,50.95538461538462,53.29615384615384,55.636923076923075,57.97769230769231,60.318461538461534,62.65923076923077,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >